Vyome Holdings, Inc. (NASDAQ:HIND) Sees Large Decline in Short Interest

Vyome Holdings, Inc. (NASDAQ:HIND) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 128,513 shares, a decline of 38.2% from the February 26th total of 208,107 shares. Based on an average daily trading volume, of 50,637 shares, the days-to-cover ratio is currently 2.5 days. Currently, 2.7% of the shares of the stock are sold short.

Vyome Price Performance

Shares of NASDAQ:HIND traded down $0.06 during trading on Friday, reaching $2.15. The company had a trading volume of 13,913 shares, compared to its average volume of 899,619. The company has a fifty day moving average price of $2.65. The stock has a market cap of $15.06 million, a PE ratio of -0.02 and a beta of 1.34. Vyome has a 12 month low of $1.75 and a 12 month high of $305.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Vyome in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $15.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vyome stock. Geode Capital Management LLC purchased a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome as of its most recent SEC filing. 22.06% of the stock is owned by institutional investors.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.